DXCM vs EW vs ZBH
161 measures in 16 categories, one definition each, computed from filings and market data.
EW64.7
Edwards Lifesciences Corporation
Healthcare · Medical - Devices
$86.60 −1.70%$49.9B mkt cap
Score DNA
ZBH59.6
Zimmer Biomet Holdings, Inc.
Healthcare · Medical - Devices
$94.98 +0.63%$18.1B mkt cap
Score DNA
Price, rebased to 100 three years ago
DXCM EW ZBH · weekly adjusted closesSmart money 8Valuation 16Profitability (TTM) 12Returns on capital 11Growth 17Margin history & stability 7Liquidity (latest quarter) 7Leverage & solvency (latest quarter) 13Efficiency 11Cash flow & earnings quality 7Dividends & buybacks 9Scores & forensic checks 15Per share 7Size (TTM) 8Price performance 9Technicals 4
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.
Smart money
8 measures| Measure | DXCM | EW | ZBH |
|---|---|---|---|
| Insider open-market buys, 180d | 0 | 0 | 0 |
| Insider $ bought, 180d | — | — | — |
| Congress purchases, 180d | 1 | 2 | 2 |
| Last Congress purchase | 2026-05-01 | 2026-05-01 | 2026-09-11 |
| 13F net change in holders | +14 | +46 | +1 |
| ETFs adding shares, 30d | 1,144 | 1,345 | 913 |
| ETFs trimming, 30d | 1,098 | 1,066 | 777 |
| Net ETF funds, 30d | +46 | +279 | +136 |
Valuation
16 measures| Measure | DXCM | EW | ZBH |
|---|---|---|---|
| P/E (TTM) | 32.5x
63rd
|
49.7x
89th
|
22.5x
33rd
|
| PEG (P/E ÷ 3-yr EPS CAGR) | 0.71
27th
|
— | 1.11
47th
|
| Price / sales | 6.5x
78th
|
7.7x
82nd
|
2.1x
23rd
|
| Price / book | 12.4x
91st
|
4.7x
61st
|
1.4x
16th
|
| Price / tangible book | 10.6x
71st
|
7.2x
54th
|
— |
| Price / free cash flow | 23.1x
42nd
|
34.8x
69th
|
9.9x
11th
|
| Price / operating cash flow | 18.6x
42nd
|
29.0x
70th
|
10.4x
14th
|
| Enterprise value | $31.9B
90th
|
$46.4B
93rd
|
$25.2B
88th
|
| EV / sales | 6.4x
78th
|
7.1x
82nd
|
3.0x
42nd
|
| EV / EBITDA | 20.5x
61st
|
29.3x
76th
|
11.3x
29th
|
| EV / EBIT | 24.6x
48th
|
32.7x
73rd
|
20.5x
42nd
|
| EV / free cash flow | 22.7x
33rd
|
32.3x
56th
|
13.8x
14th
|
| Earnings yield | 3.1%
72nd
|
2.0%
60th
|
4.5%
85th
|
| FCF yield | 4.3%
75th
|
2.9%
58th
|
10.1%
93rd
|
| Operating cash flow yield | 5.4%
70th
|
3.4%
50th
|
9.6%
90th
|
| Graham number (per share) | $19.60
22nd
|
$26.83
30th
|
$78.52
81st
|
Profitability (TTM)
12 measures| Measure | DXCM | EW | ZBH |
|---|---|---|---|
| Gross margin | 62.5%
47th
|
78.0%
87th
|
69.9%
68th
|
| EBITDA margin | 31.4%
95th
|
24.3%
83rd
|
26.2%
88th
|
| Operating margin | 22.9%
95th
|
28.1%
97th
|
15.7%
80th
|
| EBIT margin | 26.1%
95th
|
21.8%
92nd
|
14.4%
77th
|
| Net margin | 20.1%
95th
|
15.4%
90th
|
9.5%
73rd
|
| NOPAT margin | 17.9%
90th
|
19.4%
92nd
|
13.6%
80th
|
| FCF margin | 28.3%
98th
|
22.0%
93rd
|
21.5%
90th
|
| Operating cash flow margin | 35.2%
100th
|
26.4%
95th
|
20.5%
80th
|
| R&D / revenue | 12.2%
64th
|
16.7%
73rd
|
5.2%
22nd
|
| SG&A / revenue | 27.4%
13th
|
33.8%
25th
|
40.3%
33rd
|
| Stock comp / revenue | 3.3%
48th
|
2.6%
47th
|
1.2%
17th
|
| Effective tax rate | 21.9%
79th
|
31.0%
91st
|
13.6%
9th
|
Returns on capital
11 measures| Measure | DXCM | EW | ZBH |
|---|---|---|---|
| ROE (on average equity) | 38.5%
100th
|
9.5%
66th
|
6.4%
63rd
|
| ROA | 14.5%
97th
|
7.3%
77th
|
3.5%
63rd
|
| ROIC | 42.9%
97th
|
17.9%
85th
|
5.9%
61st
|
| ROCE | 31.6%
98th
|
11.5%
80th
|
6.2%
58th
|
| Return on tangible assets | 18.8%
98th
|
10.4%
83rd
|
5.4%
60th
|
| Cash ROIC (OCF / invested capital) | 84.4%
100th
|
24.3%
85th
|
8.9%
58th
|
| Gross profitability (GP / assets) | 48.1%
63rd
|
36.6%
52nd
|
26.1%
28th
|
| ROIC, 3-yr average | 26.2%
94th
|
28.3%
96th
|
4.6%
61st
|
| ROIC, 5-yr average | 23.1%
94th
|
45.2%
96th
|
3.7%
59th
|
| ROE, 5-yr average | 22.7%
94th
|
23.0%
96th
|
5.4%
65th
|
| Incremental ROIC | -39.1%
25th
|
— | — |
Growth
17 measures| Measure | DXCM | EW | ZBH |
|---|---|---|---|
| Revenue growth (TTM YoY) | 15.5%
64th
|
14.6%
59th
|
8.6%
41st
|
| Revenue growth (QoQ) | 9.8%
60th
|
5.6%
40th
|
4.3%
28th
|
| Revenue CAGR, 3 yr | 15.8%
64th
|
6.3%
30th
|
5.7%
26th
|
| Revenue CAGR, 5 yr | 18.0%
69th
|
5.7%
23rd
|
2.9%
10th
|
| Gross profit CAGR, 3 yr | 14.9%
65th
|
6.4%
25th
|
4.8%
19th
|
| Operating income CAGR, 3 yr | 36.5%
76th
|
4.4%
28th
|
15.3%
60th
|
| Net income growth (TTM YoY) | 74.9%
88th
|
-75.8%
4th
|
-2.0%
42nd
|
| Net income CAGR, 3 yr | 40.9%
80th
|
-10.2%
15th
|
16.9%
65th
|
| EPS growth (TTM YoY) | 82.2%
88th
|
-75.3%
4th
|
0.8%
42nd
|
| EPS CAGR, 3 yr | 45.5%
80th
|
-8.6%
10th
|
20.2%
60th
|
| EPS CAGR, 5 yr | 15.5%
70th
|
-5.6%
15th
|
-0.8%
30th
|
| FCF growth (TTM YoY) | 146.1%
87th
|
135.8%
83rd
|
28.5%
53rd
|
| FCF CAGR, 3 yr | 44.5%
62nd
|
28.1%
46th
|
21.1%
38th
|
| Operating cash flow CAGR, 3 yr | 31.4%
68th
|
22.3%
61st
|
8.9%
23rd
|
| Book value CAGR, 3 yr | 11.2%
65th
|
20.7%
86th
|
3.6%
47th
|
| Dividend CAGR, 3 yr | — | — | 2.1%
38th
|
| Sustainable growth rate | 38.5%
100th
|
9.5%
41st
|
4.9%
26th
|
Margin history & stability
7 measures| Measure | DXCM | EW | ZBH |
|---|---|---|---|
| Gross margin, 3-yr average | 61.3%
43rd
|
78.5%
89th
|
70.9%
74th
|
| Operating margin, 3-yr average | 18.7%
92nd
|
27.2%
98th
|
16.1%
83rd
|
| Net margin, 3-yr average | 16.8%
92nd
|
38.8%
100th
|
11.1%
79th
|
| FCF margin, 3-yr average | 19.5%
96th
|
14.3%
81st
|
18.1%
94th
|
| Revenue stability (0-1) | 0.99
96th
|
0.77
28th
|
0.66
15th
|
| Earnings stability (0-1) | 0.54
70th
|
0.07
13th
|
0.10
17th
|
| Margin stability (0-1) | 0.94
26th
|
0.98
94th
|
0.99
96th
|
Liquidity (latest quarter)
7 measures| Measure | DXCM | EW | ZBH |
|---|---|---|---|
| Cash & short-term investments | $1.9B
92nd
|
$4.3B
97th
|
$410.0M
67th
|
| Net cash (− = net debt) | $548.6M
97th
|
$3.5B
100th
|
−$7.1B
8th
|
| Working capital | $1.7B
85th
|
$5.3B
95th
|
$2.1B
92nd
|
| Current ratio | 1.73
20th
|
4.52
68th
|
1.69
18th
|
| Quick ratio | 1.43
28th
|
3.77
70th
|
1.69
37th
|
| Cash ratio (cash + ST investments / current liabilities) | 0.83
47th
|
2.82
72nd
|
0.14
12th
|
| Defensive interval (days) | 600 days
85th
|
585 days
83rd
|
173 days
15th
|
Leverage & solvency (latest quarter)
13 measures| Measure | DXCM | EW | ZBH |
|---|---|---|---|
| Total debt | $1.4B
82nd
|
$704.4M
58th
|
$7.5B
92nd
|
| Debt / equity | 0.53
49th
|
0.07
21st
|
0.59
54th
|
| Net debt / equity | −0.21
37th
|
−0.33
26th
|
0.56
68th
|
| Debt / assets | 21.7%
43rd
|
5.1%
18th
|
32.8%
63rd
|
| Debt / capital | 34.8%
49th
|
6.2%
21st
|
37.2%
54th
|
| Debt / EBITDA | 0.90
18th
|
0.45
16th
|
3.36
61st
|
| Net debt / EBITDA | −0.35
32nd
|
−2.24
8th
|
3.17
66th
|
| Interest coverage (EBIT / interest) | 86.3x
92nd
|
— | 4.3x
65th
|
| Cash interest coverage | 116.6x
92nd
|
— | 6.0x
67th
|
| Debt payback (years of OCF) | 0.8 yrs
21st
|
0.4 yrs
14th
|
4.3 yrs
58th
|
| Liabilities / assets | 59.4%
70th
|
22.7%
17th
|
44.6%
42nd
|
| IS credit model rating | AAA | AA+ | BBB |
| Implied credit spread (bps) | 50
0th
|
65
8th
|
275
53rd
|
Efficiency
11 measures| Measure | DXCM | EW | ZBH |
|---|---|---|---|
| Asset turnover | 0.72
62nd
|
0.48
22nd
|
0.37
10th
|
| Fixed asset turnover | 2.98
12th
|
3.35
16th
|
3.80
28th
|
| Inventory turnover | 2.9
79th
|
1.3
19th
|
2.1
67th
|
| Receivables turnover | 3.8
8th
|
8.9
92nd
|
5.0
25th
|
| Days sales outstanding | 96 days
92nd
|
41 days
8th
|
73 days
75th
|
| Days inventory outstanding | 127 days
21st
|
289 days
81st
|
175 days
33rd
|
| Days payables outstanding | 88 days
78th
|
47 days
40th
|
50 days
47th
|
| Cash conversion cycle (days) | 135 days
30th
|
283 days
85th
|
197 days
45th
|
| Capex / revenue | 6.9%
90th
|
4.4%
64th
|
— |
| Capex / depreciation | 1.30
74th
|
1.73
79th
|
— |
| Operating expense ratio | 39.1%
10th
|
47.7%
29th
|
55.8%
41st
|
Cash flow & earnings quality
7 measures| Measure | DXCM | EW | ZBH |
|---|---|---|---|
| Operating cash flow / net income | 1.75
63rd
|
1.71
56th
|
2.16
78th
|
| FCF / net income | 1.41
59th
|
1.43
63rd
|
2.27
89th
|
| FCF / operating cash flow | 80.3%
69th
|
83.3%
74th
|
— |
| Capex / operating cash flow | 19.7%
31st
|
16.7%
26th
|
— |
| Accruals ratio | -10.9%
22nd
|
-5.2%
50th
|
-4.1%
63rd
|
| Sloan accruals ratio | -3.7%
38th
|
-0.2%
55th
|
-5.6%
32nd
|
| Earnings quality score (0-1) | 0.75
4th
|
0.75
4th
|
1.00
48th
|
Scores & forensic checks
15 measures| Measure | DXCM | EW | ZBH |
|---|---|---|---|
| IS score | 81
98th
|
65
83rd
|
60
73rd
|
| IS profitability | 83
98th
|
64
83rd
|
45
62nd
|
| IS growth | 72
79th
|
33
12th
|
44
23rd
|
| IS value | 32
30th
|
36
37th
|
65
93rd
|
| IS momentum | 94
95th
|
64
39th
|
74
61st
|
| IS risk (safety) | 100
62nd
|
100
62nd
|
50
35th
|
| IS quality | 91
98th
|
82
85th
|
72
67th
|
| IS balance sheet | 86
80th
|
94
98th
|
50
47th
|
| IS earnings quality | 53
37th
|
75
82nd
|
71
70th
|
| IS cash flow | 90
100th
|
89
97th
|
77
87th
|
| Piotroski F-score (0-9) | 9
95th
|
6
47th
|
6
47th
|
| Altman Z-score | 6.5
70th
|
12.7
88th
|
2.4
37th
|
| Beneish M-score | −3.13
14th
|
−2.66
52nd
|
−2.59
61st
|
| Ohlson O-score | −8.62
30th
|
−10.85
8th
|
−8.82
27th
|
| IS credit score | 95
93rd
|
93
88th
|
57
43rd
|
Size (TTM)
8 measures| Measure | DXCM | EW | ZBH |
|---|---|---|---|
| Market cap | $32.5B
92nd
|
$49.9B
93rd
|
$18.1B
88th
|
| Revenue | $5.0B
87th
|
$6.5B
88th
|
$8.5B
90th
|
| EBITDA | $1.6B
87th
|
$1.6B
88th
|
$2.2B
90th
|
| Net income | $999.7M
88th
|
$1.0B
90th
|
$806.8M
87th
|
| Free cash flow | $1.4B
88th
|
$1.4B
90th
|
$1.8B
93rd
|
| Total assets | $6.5B
83rd
|
$13.9B
90th
|
$22.8B
92nd
|
| Shareholders' equity | $2.6B
80th
|
$10.6B
90th
|
$12.6B
93rd
|
| Employees | 11,050
82nd
|
16,000
87th
|
17,000
88th
|
Price performance
9 measures| Measure | DXCM | EW | ZBH |
|---|---|---|---|
| 1 day | −1.9% | −1.7% | +0.6% |
| 1 week | +2.3% | +1.6% | +6.5% |
| 1 month | −2.1% | −1.9% | +1.0% |
| 3 months | +13.7% | +1.9% | +5.8% |
| 6 months | +34.5% | +6.9% | +0.2% |
| Year to date | +29.3% | +1.5% | +5.5% |
| 1 year | +31.5% | +18.7% | −4.4% |
| 3 years, cumulative | +8.9% | +21.7% | −8.4% |
| 5 years, cumulative | −35.0% | −20.4% | −31.2% |
Technicals
4 measures| Measure | DXCM | EW | ZBH |
|---|---|---|---|
| RSI 14 | 50.3 | 49.2 | 57.5 |
| From 52-week high | −7.1% | −10.1% | −11.1% |
| From 52-week low | +59.0% | +19.6% | +20.0% |
| Beta | 1.48 | 0.86 | 0.48 |
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17